Marathon to buy pharma company

Marathon Asset Management signed a deal to acquire Kaléo for $310 million in cash as the firm boosts its healthcare-oriented investments.

Richmond, Virginia-based Kaléo is a privately held pharmaceutical company that serves patients at risk for anaphylaxis and other serious life-threatening conditions. The deal will offer liquidity for Kaléo shareholders upon closing in a series of cash payments through 2023.

“The sales trajectory of Kaléo has been impressive, and we view the company as a platform for growth,” said Dr. Evan Bedil, head of healthcare at Marathon. “We . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available.

Get started

Back to top button

Start Your Days in the Know


Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!